Sodium-Glucose Cotransporter Inhibitors in Cerebrovascular Health

Sodium-glucose cotransporter (SGLT) inhibitors, originally developed to lower blood glucose in type 2 diabetes, have emerged as modulators of cerebrovascular integrity and function. Beyond glycaemic control, these agents influence endothelial health, neuroinflammation and blood–brain barrier stability, offering potential protection against ischaemic and haemorrhagic injury. Preclinical models indicate that SGLT2 inhibitors attenuate brain oedema by reducing astrocyte swelling and preserve microvascular perfusion through pericyte support. Genetic studies link SGLT1/2 activity to markers of cerebral small vessel disease, suggesting mechanistic pathways via metabolite modulation and anti-inflammatory effects. Clinical trials originally focused on cardiovascular endpoints have reported neutral effects on total stroke risk but a noteworthy reduction in haemorrhagic stroke. Together, these data point to a repurposing opportunity for SGLT inhibitors in acute stroke management and chronic prevention of small vessel pathology, warranting further mechanistic and translational investigation.

Research from Nature Portfolio

A comprehensive meta-analysis of randomised cardiovascular outcome trials found that SGLT2 inhibitors do not alter overall stroke incidence but confer a significant 50 percent reduction in haemorrhagic stroke compared with placebo, underscoring a selective cerebrovascular benefit. In parallel, experimental work using a non-diabetic mouse model of permanent middle cerebral artery occlusion demonstrated that low-dose pre-treatment with a selective SGLT2 inhibitor reduced infarct volume, mitigated blood–brain barrier disruption and preserved motor function. These protective effects were independent of blood-glucose changes and linked to enhanced mitochondrial biogenesis and survival of brain pericytes in ischaemic regions.

Sodium-Glucose Cotransporter Inhibitors in Cerebrovascular Health publication trend

The graph below shows the total number of articles in sodium-glucose cotransporter inhibitors in cerebrovascular health across all publications each year (not limited to Nature Index journals).

Technical terms

Cerebral small vessel disease (CSVD): A spectrum of pathological changes affecting small arteries, arterioles and capillaries in the brain, leading to microbleeds, white matter lesions and lacunar infarcts.

Ischaemic stroke: Brain injury caused by interruption of blood flow due to arterial occlusion, resulting in tissue hypoxia and neuronal death.

Haemorrhagic stroke: Bleeding into brain tissue or surrounding spaces, often from vessel rupture, causing mass effect and tissue damage.

Pericyte: Contractile cell around microvessels that regulates capillary blood flow, blood–brain barrier integrity and vascular stability.

Astrocyte: Glial cell involved in metabolic support, regulation of extracellular ion balance and maintenance of the blood–brain barrier.

References

1. SGLT1 and SGLT2 inhibition, circulating metabolites, and cerebral small vessel disease: a mediation Mendelian Randomization study. Cardiovascular Diabetology (2024).
2. Canagliflozin, an Inhibitor of the Na+-Coupled D-Glucose Cotransporter, SGLT2, Inhibits Astrocyte Swelling and Brain Swelling in Cerebral Ischemia. Cells (2023).
3. Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia. Cells (2022).
4. Low-dose sodium-glucose cotransporter 2 inhibitor ameliorates ischemic brain injury in mice through pericyte protection without glucose-lowering effects. Communications Biology (2022).
5. Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis. Scientific Reports (2021).